IXICO plc (PHYOF)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3.27 Million USD | -34.78% |
| 2022 | 5.32 Million USD | -28.6% |
| 2021 | 7.45 Million USD | -2.41% |
| 2020 | 7.63 Million USD | 28.32% |
| 2019 | 5.95 Million USD | 51.08% |
| 2018 | 3.93 Million GBP | 38.38% |
| 2017 | 2.84 Million GBP | 76.61% |
| 2016 | 1.61 Million GBP | -10.04% |
| 2015 | 1.79 Million GBP | -30.29% |
| 2014 | 2.57 Million GBP | 230.67% |
| 2013 | -1.96 Million GBP | -10454.76% |
| 2012 | 19 Thousand GBP | -71.5% |
| 2011 | 66.65 Thousand GBP | -89.07% |
| 2010 | 610 Thousand GBP | -10.29% |
| 2009 | 680 Thousand GBP | -72.29% |
| 2008 | 2.45 Million GBP | 0.0% |
| 2007 | - GBP | -100.0% |
| 2006 | 1.54 Million GBP | -77.9% |
| 2005 | 6.97 Million GBP | 557.06% |
| 2004 | 1.06 Million GBP | -56.24% |
| 2003 | 2.42 Million GBP | -10.57% |
| 2002 | 2.71 Million GBP | 84.5% |
| 2001 | 1.47 Million GBP | -29.21% |
| 2000 | 2.07 Million GBP | -15.08% |
| 1999 | 2.44 Million GBP | 243.2% |
| 1998 | 713 Thousand GBP | 1484.44% |
| 1997 | 45 Thousand GBP | -95.18% |
| 1996 | 934 Thousand GBP | -16.16% |
| 1995 | 1.11 Million GBP | 731.34% |
| 1994 | 134 Thousand GBP | -55.63% |
| 1993 | 302 Thousand GBP | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 1.13 Million USD | 0.0% |
| 2023 FY | 3.47 Million USD | -34.78% |
| 2023 Q2 | 1.57 Million USD | 0.0% |
| 2023 Q4 | 1.91 Million USD | 0.0% |
| 2022 Q4 | 2.98 Million USD | 0.0% |
| 2022 Q2 | 2.78 Million USD | 0.0% |
| 2022 FY | 5.32 Million USD | -28.6% |
| 2021 Q2 | 4.23 Million USD | 0.0% |
| 2021 Q4 | 3.64 Million USD | 0.0% |
| 2021 FY | 7.45 Million USD | -2.41% |
| 2020 Q4 | 3.96 Million USD | 0.0% |
| 2020 FY | 7.63 Million USD | 28.32% |
| 2020 Q2 | 3.52 Million USD | 0.0% |
| 2019 FY | 5.95 Million USD | 51.08% |
| 2019 Q4 | 3.19 Million USD | 0.0% |
| 2018 FY | 3.93 Million GBP | 38.38% |
| 2017 FY | 2.84 Million GBP | 76.61% |
| 2016 FY | 1.61 Million GBP | -10.04% |
| 2015 FY | 1.79 Million GBP | -30.29% |
| 2014 FY | 2.57 Million GBP | 230.67% |
| 2013 FY | -1.96 Million GBP | -10454.76% |
| 2012 FY | 19 Thousand GBP | -71.5% |
| 2011 FY | 66.65 Thousand GBP | -89.07% |
| 2010 FY | 610 Thousand GBP | -10.29% |
| 2009 FY | 680 Thousand GBP | -72.29% |
| 2008 FY | 2.45 Million GBP | 0.0% |
| 2007 FY | - GBP | -100.0% |
| 2006 FY | 1.54 Million GBP | -77.9% |
| 2005 FY | 6.97 Million GBP | 557.06% |
| 2004 FY | 1.06 Million GBP | -56.24% |
| 2003 FY | 2.42 Million GBP | -10.57% |
| 2002 FY | 2.71 Million GBP | 84.5% |
| 2001 FY | 1.47 Million GBP | -29.21% |
| 2000 FY | 2.07 Million GBP | -15.08% |
| 1999 FY | 2.44 Million GBP | 243.2% |
| 1998 FY | 713 Thousand GBP | 1484.44% |
| 1997 FY | 45 Thousand GBP | -95.18% |
| 1996 FY | 934 Thousand GBP | -16.16% |
| 1995 FY | 1.11 Million GBP | 731.34% |
| 1994 FY | 134 Thousand GBP | -55.63% |
| 1993 FY | 302 Thousand GBP | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 134171.341% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 72.066% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 1123.452% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 97.255% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 112.675% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 6875.938% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 2731.77% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 78.199% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -105315.861% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 66.612% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -4875.049% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 9675.403% |
| Mesoblast Limited | -35.16 Million USD | 109.298% |
| Marizyme, Inc. | 457.7 Thousand USD | -614.439% |
| Genus plc | 178.7 Million USD | 98.17% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 98.514% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -5155.038% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -697.24% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 29827.273% |
| ContraFect Corporation | -154 Thousand USD | 2223.377% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 6640.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -4159.976% |
| IMV Inc. | -962.29 Thousand USD | 439.812% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 943.869% |
| MultiCell Technologies, Inc. | 49.32 USD | -6630070.316% |
| ONE Bio Corp. | 20.12 Million USD | 83.752% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 91.879% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -6587.117% |
| Q BioMed Inc. | -8988.00 USD | 36481.842% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 88.427% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 21300.726% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 92.628% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 386.447% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -4571.429% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 66133.926% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -2227.402% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 3453.33% |
| GB Sciences, Inc. | -624.00 USD | 524138.462% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 3901.088% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.957% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 1572215.385% |
| Enzolytics Inc. | 30.7 Thousand USD | -10548.691% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -577.814% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.705% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 735.556% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -429.654% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.202% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 37024.119% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 3999.868% |
| Kadimastem Ltd | -630.13 Thousand USD | 618.934% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -230.978% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 65.976% |
| BioStem Technologies, Inc. | 15.42 Million USD | 78.8% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 27729.911% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -1752.062% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -1752.062% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -140.947% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 11375.862% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -626.597% |
| SYBLEU INC | 11.69 Thousand USD | -27858.276% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 29.036% |
| Bioxytran, Inc. | -8285.00 USD | 39568.92% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 976.676% |
| Neutra Corp. | 14.33 Thousand USD | -22711.301% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 4087.805% |
| PureTech Health plc | -1.6 Million USD | 303.993% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 426.596% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 571.182% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 282.58% |
| CSL Limited | 7.7 Billion USD | 99.958% |
| Cellectis S.A. | 18 Thousand USD | -18066.667% |